THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.30]-C173 ID: TIP-MED-000443

Paradichlorobenzene / Benzocaine Cerumenolytic Ear Drops

Active Ingredient / Scientific Identity: Paradichlorobenzene / Benzocaine Cerumenolytic Ear Drops • Class: Topical Otic Fluoroquinolone, Imidazole Antifungal, Corticosteroid, Local Anaesthetic & Cerumenolytic Preparations

⚖️ Compare Profile
Generic / Entity NameParadichlorobenzene / Benzocaine Cerumenolytic Ear Drops ([12.30]-C173)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassTopical Otic Fluoroquinolone, Imidazole Antifungal, Corticosteroid, Local Anaesthetic & Ce
Available Dosage FormsCiprofloxacin 0.3% w/v (+ Dexamethasone 0.1% w/v) Sterile Drops (5 mL, 10 mL). Clotrimazole 1% w/v + Beclometh
Regulatory ClassificationSchedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register un
Key Warning & Review DateRenal & Hepatic: No systemic dose adjustment required.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 Prescription Drug (Mandatory Red-Bordere✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Paradichlorobenzene / Benzocaine Cerumenolytic Ear Drops (TIP-MED-000443, Reference Code [12.30]-C173) is classified under Ophthalmological & Otic (ENT) Preparations (Ch 12) as a Topical Otic Fluoroquinolone, Imidazole Antifungal, Corticosteroid, Local Anaesthetic & Cerumenolytic Preparations. Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [12.30] (Otic Ciprofloxacin, Clotrimazole & Cerumenolytic Ear Drops). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.30], p. 169): Antibiotic/Steroid Otic: Ciplox-D (Cipla — Ciprofloxacin 0.3% + Dexamethasone 0.1%), Allegra-O / Otek-AC; Antifungal Otic: Candibiotic Plus (Glenmark — Clotrimazole 1% + Beclomethasone + Lignocaine), Candid Ear Drops; Cerumenolytic: Soliwax (NuLife), Clearwax (Cipla), Waxolve — Strengths & Dosage Forms: Ciprofloxacin 0.3% w/v (+ Dexamethasone 0.1% w/v) Sterile Drops (5 mL, 10 mL). Clotrimazole 1% w/v + Beclomethasone Dipropionate 0.025% w/v + Lignocaine HCl 2% w/v Ear Drops (5 mL, 10 mL). Paradichlorobenzene 2% + Benzocaine 2.7% + Chlorbutol 5% + Turpentine Oil 15% Ear Drops (10 mL).
Co-indexed constituent under primary monograph [12.30] (Otic Ciprofloxacin, Clotrimazole & Cerumenolytic Ear Drops). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.30], p. 169): Antibiotic/Steroid Otic: Ciplox-D (Cipla — Ciprofloxacin 0.3% + Dexamethasone 0.1%), Allegra-O / Otek-AC; Antifungal Otic: Candibiotic Plus (Glenmark — Clotrimazole 1% + Beclomethasone + Lignocaine), Candid Ear Drops; Cerumenolytic: Soliwax (NuLife), Clearwax (Cipla), Waxolve — Strengths & Dosage Forms: Ciprofloxacin 0.3% w/v (+ Dexamethasone 0.1% w/v) Sterile Drops (5 mL, 10 mL). Clotrimazole 1% w/v + Beclomethasone Dipropionate 0.025% w/v + Lignocaine HCl 2% w/v Ear Drops (5 mL, 10 mL). Paradichlorobenzene 2% + Benzocaine 2.7% + Chlorbutol 5% + Turpentine Oil 15% Ear Drops (10 mL).
Dosage Forms & Available Strengths:
Ciprofloxacin 0.3% w/v (+ Dexamethasone 0.1% w/v) Sterile Drops (5 mL, 10 mL). Clotrimazole 1% w/v + Beclomethasone Dipropionate 0.025% w/v + Lignocaine HCl 2% w/v Ear Drops (5 mL, 10 mL). Paradichlorobenzene 2% + Benzocaine 2.7% + Chlorbutol 5% + Turpentine Oil 15% Ear Drops (10 mL).
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Ciprofloxacin inhibits bacterial DNA gyrase (Pseudomonas/Staph in otitis externa); Clotrimazole inhibits fungal ergosterol synthesis (otomycosis); Paradichlorobenzene + Turpentine emulsify impacted cerumen.

4. Therapeutic Indications & Evidence-Supported Uses

  • Acute diffuse otitis externa ('swimmer's ear' — Ciprofloxacin/Steroid drops), fungal otitis externa / otomycosis (Aspergillus/Candida — Clotrimazole drops), and softening/dissolution of impacted earwax prior to syringing (Cerumenolytic drops)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Otitis Externa / Otomycosis: Instil 3–4 drops into the affected ear canal TDS–QDS for 7–10 days. Impacted Cerumen: Instil 5–10 cerumenolytic drops into the ear canal BD–TDS for 3–4 days, plugging gently with a moistened cotton pledget (avoid dry cotton wool which wicks away the active drops!).

Administration & Meal Timing: Topical otic instillation Only — NEVER instil ear-only glycerine/cerumenolytic drops into the eyes! | 3 to 4 times daily; warm bottle in palms for 1–2 minutes before instillation.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [12.30].
Metabolism & Biotransformation:
Renal & Hepatic: No systemic dose adjustment required.
Elimination & Renal Adjustment:
Renal & Hepatic: No systemic dose adjustment required.
Hepatic Impairment Considerations:
Renal & Hepatic: No systemic dose adjustment required.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • TYMPANIC MEMBRANE PERFORATION RULE (OTOTOXICITY): In known or suspected perforated eardrum or grommet tubes, STRICTLY AVOID Aminoglycoside ear drops (Gentamicin, Neomycin, Framycetin, Polymyxin B) and Cerumenolytics/Alcohol (cause irreversible cochlear/vestibular deafness!). Non-ototoxic Ciprofloxacin 0.3% otic drops are the only safe choice when perforation is present.

Key Clinical Precautions: Renal & Hepatic: No systemic dose adjustment required.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Transient stinging/burning on instillation, local pruritus, temporary muffled hearing (as cerumen swells upon absorbing cerumenolytic drops — warn patient in advance!).
  • Cochlear and vestibular ototoxicity (if aminoglycoside/chloramphenicol/cerumenolytic drops enter middle ear through a perforated drum), secondary fungal overgrowth (prolonged antibiotic/steroid drops >10 days), contact dermatitis (Benzocaine/Neomycin).
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Minimal systemic absorption; avoid concurrent use of two different otic solutions without a 30-minute interval

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [12.30].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Hold dropper bottle in warm hands for 2 minutes before use (cold ear drops cause severe vertigo/dizziness!); lie on side with affected ear up, pull pinna upward & backward (downward & backward in children <3 yr), instil drops, press tragus 4 times, and stay tilted for 5 minutes.
    • Meal & Clock Timing Instruction: Topical otic instillation Only — NEVER instil ear-only glycerine/cerumenolytic drops into the eyes! (3 to 4 times daily; warm bottle in palms for 1–2 minutes before instillation.)
    • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
    • Geriatric Dispensing Pearl: Schedule: Schedule H (Antibiotic/Steroid Otic) / OTC (Cerumenolytic) | NLEM 2022: Yes (Ciprofloxacin 0.3% Drops, Clotrimazole 1% Drops) | Compendia: NFI 7th Ed 2026 / NLEM 2022

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ciprofloxacin 0.3% w/v (+ Dexamethasone 0.1% w/v) Sterile Drops (5 mL, 10 mL). Clotrimazole 1% w/v + Beclomethasone Dipropionate 0.025% w/v + Lignocaine HCl 2% w/v Ear Drops (5 mL, 10 mL). Paradichlorobenzene 2% + Benzocaine 2.7% + Chlorbutol 5% + Turpentine Oil 15% Ear Drops (10 mL).

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.